Latest Impairment News

Page 12 of 54
ARB Corporation’s half-year results reveal a modest sales dip driven by Australian OEM challenges, while robust US export growth offers a silver lining.
Victor Sage
Victor Sage
20 Jan 2026
James Hardie Industries is set to close its Fontana and Summerville manufacturing plants, consolidating production to boost efficiency and cut costs by $25 million annually starting next fiscal year.
Victor Sage
Victor Sage
16 Jan 2026
Endeavour Group reports modest sales growth in the first half of FY26, driven by strong momentum at Dan Murphy’s and BWS, despite retail margin compression from price investments. Significant one-off costs related to warehouse changes weigh on profits.
Victor Sage
Victor Sage
13 Jan 2026
Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.
Ada Torres
Ada Torres
7 Jan 2026
Central Petroleum has amended its sub-salt exploration permit sale, excluding the EP82 permit and retaining Helium Australia Pty Ltd, while anticipating a $4.2 million impairment charge in FY26.
Maxwell Dee
Maxwell Dee
19 Dec 2025
nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.
Ada Torres
Ada Torres
19 Dec 2025
Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.
Ada Torres
Ada Torres
18 Dec 2025
Locality Planning Energy Holdings has reached a confidential settlement over its Harbour Towers dispute, anticipating a net gain and cash inflow in FY2026. This resolution reverses prior impairment losses and signals a positive financial turn for the embedded energy provider.
Maxwell Dee
Maxwell Dee
18 Dec 2025
Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.
Claire Turing
Claire Turing
15 Dec 2025
Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.
Ada Torres
Ada Torres
11 Dec 2025
Bapcor Limited has revised its first-half FY26 guidance to a statutory net loss, citing weaker trade segment performance and one-off costs, while maintaining a cautiously optimistic full-year outlook supported by cost savings and leadership changes.
Logan Eniac
Logan Eniac
9 Dec 2025
Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.
Ada Torres
Ada Torres
4 Dec 2025